![]() |
| Novel Non-Absorbed Therapeutics |
| COMPANY OVERVIEW | IN THE NEWS |
Relypsa is a clinical-stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal diseases. Relypsa's lead product candidate is RLY5016, a non- absorbed potassium binder for the treatment of hyperkalemia. Relypsa is pursuing the discovery of additional product candidates through use of its proprietary polymer platform. Privately-held, Relypsa’s investors include: OrbiMed, 5AM Ventures, Delphi Ventures, Mediphase Venture Partners, New Leaf Venture Partners, Sprout Group and Amgen. |
October 25, 2011 NEW June 28 , 2011 May 23, 2011 May 19, 2011
|
|
© 2010 Relypsa, Inc |